TThe University of Chicago Medicine provides comprehensive healthcare through its Hyde Park campus, regional facilities, and outpatient clinics, backed by the Medical Center, Pritzker School of Medicine, and the Biological Sciences Division. It offers specialized care across more than 40 institutes and centers, including an NCI-designated Comprehensive Cancer Center, with 805 licensed beds, about 850 attending physicians, around 2,500 nurses, and over 1,100 residents and fellows. Care is delivered by clinical teams in hospitals and clinics, with ongoing research and education that translate new knowledge into treatments and train the next generation of clinicians. As an academic medical center that links a hospital system with a medical school and biology division, it combines patient care, medical education, and biomedical research while serving a regional network in the Chicago area.
Work here?Claim your company
Industries
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$112.4M
Headquarters
Chicago, Illinois
Founded
1927
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$112.4M
Above
Industry Average
Funded Over
3 Rounds
UChicago Medicine launches homegrown cell therapy for advanced solid tumors. Newswise - Researchers at UChicago Medicine have launched a first-of-its-kind clinical trial testing a new type of personalized cell therapy designed to help the body's own immune system recognize and destroy cancer cells. The study will evaluate the treatment's safety and early effectiveness in patients with metastatic ovarian cancer and several other advanced solid tumors. Cell therapy is one of the most promising advances in cancer treatment. It involves collecting a patient's own immune cells, genetically reprogramming them in the laboratory to better recognize cancer, and then infusing them back into the patient. Once inside the body, these enhanced immune cells are designed to seek out and destroy cancer cells while leaving healthy tissue largely untouched. The approach has already transformed treatment for some blood cancers, and researchers are now working to bring those same benefits to patients with solid tumors. Leaders in cell therapy UChicago Medicine has been at the forefront of this field. It was among the first medical centers in the country to offer FDA-approved CAR T-cell therapy for adults and children with certain blood cancers and, more recently, became one of the first centers to provide tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma. This new trial marks another major milestone. For the first time, UChicago Medicine researchers will design, manufacture and administer an experimental cell therapy entirely on campus, without relying on a pharmaceutical company to produce the cells. The treatment also takes a different approach than existing CAR T-cell therapies. Instead of using engineered receptors that recognize proteins on the surface of cancer cells, the researchers are using specially engineered T-cell receptors, which allow immune cells to detect proteins hidden inside cancer cells. This greatly expands the number of cancers that may be targeted. "We're using the same natural process the immune system relies on to fight infections, but we're redirecting it to attack cancer," said Richard Koya, MD, PhD, Professor of Obstetrics and Gynecology at UChicago Medicine, the scientific investigator who developed the treatment and designed the clinical trial based on many years of laboratory research. "Our goal is to create immune cells that can recognize cancer more effectively, survive longer and continue fighting the disease." A novel approach For the study, doctors will first collect a patient's white blood cells. Patients will then receive the chemotherapy drug decitabine, which increases production of a cancer protein called NY-ESO-1 - a target found in many tumors but not in healthy adult tissues. In the laboratory, researchers will genetically engineer the patient's immune cells with two important features. The first is a T-cell receptor that recognizes NY-ESO-1, helping the cells identify and attack cancer. The second is a genetic modification that blocks TGF-beta, a signaling molecule that normally suppresses immune responses and contributes to T-cell exhaustion inside tumors. The enhanced immune cells will then be infused back into the patient through an intravenous line, similar to a blood transfusion. Patients will also receive a low dose of the immune-boosting drug interleukin-2 to help the engineered T cells multiply and remain active. Researchers believe this combination could produce a stronger and longer-lasting immune response because it addresses one of the biggest challenges in treating solid tumors: the hostile environment that often weakens cancer-fighting immune cells before they can eliminate the tumor. Home-grown treatment The clinical trial is unique in several important ways. First, it is an investigator-initiated clinical trial, meaning the treatment was conceived of and developed by University of Chicago researchers rather than a pharmaceutical or biotechnology company. With one of the nation's largest cancer clinical trials programs, the UChicago Medicine Comprehensive Cancer Center has extensive experience translating laboratory discoveries into early-stage clinical studies. Second, the engineered cells will be produced in UChicago Medicine's Good Manufacturing Practices (GMP) facility, a highly specialized laboratory that meets strict federal standards for producing cell therapies. Manufacturing the cells on-site allows researchers to oversee every step of the process while accelerating the translation of discoveries from the laboratory to patients. "Very few academic medical centers have the ability to manufacture personalized cell therapies entirely on-site," Koya said. "This gives us tremendous flexibility to rapidly test new ideas and move promising treatments to patients." Finally, the Phase 1/2A trial will evaluate the experimental therapy in a small group of patients with metastatic ovarian cancer, soft tissue sarcoma, bladder cancer, prostate cancer, breast cancer, melanoma or non-small cell lung cancer - all cancers that form solid tumors. Unlike blood cancers, where CAR T-cell therapies have shown remarkable success, solid tumors have proven much more difficult to treat because they create an environment that suppresses immune cells. By engineering T cells to resist suppressive signals such as TGF-beta, researchers hope the cells will persist longer, develop lasting immune memory and continue attacking tumors over time. The investigators plan to infuse approximately one billion engineered T cells into each patient, with the goal of generating a powerful and durable immune response against cancers that currently have few effective treatment options. Beginning in October 2026, screening for eligible patients will take place at UChicago Medicine locations in Hyde Park, New Lenox, Harvey, Flossmoor, Calumet City, Tinley Park and Crown Point, Indiana. Treatment will take place at the main campus in Hyde Park. UChicago Medicine oncologist Daniel Olson, MD, Assistant Professor of Medicine, is the clinical investigator overseeing the trial. Thinle Chodon, MD, PhD, research professor, is overseeing production of the engineered cells in UChicago Medicine's GMP facility. UChicago Medicine and the Biological Sciences Division continue to be at the forefront of cancer care and research. In April 2027, UChicago Medicine will open the AbbVie Foundation Cancer Pavilion, Chicago's first freestanding cancer pavilion, to bring advanced diagnostics, innovative treatments, translational discoveries, and comprehensive support to patients and the community. Media contact. Type of article. Section.
UChicago Medicine plans $328 million laboratory on Chicago's south side. The University of Chicago Medicine asked state regulators to approve plans for a $328 million laboratory facility on the city's south side.
New details emerge of UChicago, City Colleges' Washington Park lab campus. October 07, 2026 05:15 AM CDT UChicago Medicine plans to build a four-story, nearly $328 million clinical lab building along Garfield Boulevard near Washington Park, in a collaboration with the City College of Chicago, which will follow it up with a four-story Malcolm X College lab technician training center on adjacent property. Access this content, additional healthcare industry coverage, exclusive newsletters and more. Health Pulse - Annual $399 for 1 year, renews automatically These 14 families wield influence across Chicago and Illinois through business, politics, philanthropy, sports and civic institutions.
UChicago Medicine names 1st AI, data chief. By: Giles Bruce University of Chicago Medicine has appointed Josh Denny, MD, its inaugural senior vice president for AI and precision medicine and chief data officer, effective November 2026. Dr. Denny, who will also serve as vice dean, has been CEO of the NIH's All of Us Research Program since 2020, overseeing a national research initiative that has enrolled nearly 900,000 participants and generated more than 535,600 whole genome sequences. He previously spent more than two decades at Nashville, Tenn.-based Vanderbilt Health, where he founded the Center for Precision Medicine and developed phenome-wide association studies, a method that scans patient records for conditions linked to genetic variants. At UChicago Medicine, Dr. Denny will work across the health system, research division and university to connect AI, genomics and clinical informatics. UChicago has contributed nearly 16,000 participants to All of Us and leads the Illinois Precision Medicine Consortium, which has enrolled more than 62,000 participants statewide. The appointment builds on UChicago Medicine's Elevate 2035 strategic plan to unite research, clinical care and technology. Monday, September 28 12:00 PM - 1:00 PM CDT Presenters: Cathie Abrahamsen, RN, MSN, DNV Healthcare|MaryJo Barnett, RN, MSN, CRRN, HCA Florida West Marion Hospital|Neda Mitova-Caneva, PT, MPT, GCS, West Marion IRF Next up in executive moves. * Ascension Saint Thomas taps new vice president of joint ventures Jeremy Mercer was named vice president of joint ventures and chief integration officer of Ascension Saint Thomas in Nashville, Tenn.,... By: Madeline Scheetz * WVU Medicine taps 6 new leaders Morgantown, W.Va.-based WVU Medicine has named six new leaders across the health system. Amy Bush was appointed president of WVU... By: Madeline Scheetz * Texas Health names hospital president Arlington-based Texas Health Resources named Jon Duckert president of Texas Health Harris Methodist Hospital Southlake, effective Oct. 1. Mr. Duckert... By: Kristin Kuchno
How UChicago Medicine shifted staff to 'more difficult' revenue cycle work. By: Alan Condon UChicago Medicine is using automation to move revenue cycle staff away from routine insurance and prior authorization tasks and into more complex cases that require human judgment. Matthew Kennedy, director of patient access and financial clearance at UChicago Medicine, discussed the health system's strategy during a panel at Becker's 11th Annual Health IT + Digital Health + RCM Conference and said the system had significant amounts of manual work tied to insurance verification, prior authorization, imaging and routine procedures. "We didn't have anything broken so much as we had a lot of manual work," Mr. Kennedy said. UChicago Medicine partnered with a vendor to automate portions of that workload through Epic-integrated workflows. Routine cases can now be checked automatically, while exceptions are routed to staff for further review. Now the health system is clearing about 95% of certain cases up to 28 days before the scheduled service - roughly 12 days earlier than before. "It really helped take care of a lot of the imaging work, a lot of those simpler surgeries," he said. The technology is best suited for more predictable cases, according to Mr. Kennedy, who said more complex procedures still require experienced employees to review clinical documentation, payer requirements and other details. "AI is not going to know the clinicals that you're going to pull," he said. "It's not going to know the information to help get that verification or that authorization." UChicago Medicine has not reduced headcount as a result of the automation. Instead, employees have been reassigned to more complicated work. "AI does not mean that you're going to lose staff," Mr. Kennedy said. "Your colleagues aren't going anywhere. They have this depth of knowledge. But we were able to move them to those more difficult things." That expertise is being redirected toward areas such as complex surgeries, labor plans, payer follow-up and cases where prior authorization or predetermination requirements are unclear. Mr. Kennedy also cautioned against treating AI as a fully autonomous solution. "AI automation is a really cool tool, but it's just a tool," he said. "You shouldn't rely solely on it." He said UChicago Medicine maintains teams that review automation results and monitor payer changes rather than simply accepting what technology or vendors return. "I love skeptics," Mr. Kennedy said. "AI is not a 'set it and forget it' thing. AI is going to make mistakes." Those employees can help identify changes in payer rules, portal requirements or documentation standards before they create larger problems. Mr. Kennedy said successful automation also depends on adoption by employees. "Implementation and adoption - those are two different things," he said. "Just because you have that tool, it doesn't mean that it's being used appropriately. It doesn't mean it's being used correctly." For UChicago Medicine, the goal is not to automate every revenue cycle task, but to use technology where it can reliably handle routine work and preserve employee expertise for cases that require more judgment. "It's better to put them towards those exceptions, those difficult cases," Mr. Kennedy said. Tuesday, September 29 1:00 PM - 2:00 PM CDT Presenters: Frank Stevens, Strata|Josh Wiggins, Strata Next up in revenue cycle management. * Kaiser to lay off 147 workers across California Kaiser Permanente is laying off 147 employees across several cities in California, the Oakland-based health system said in regulatory documents... By: Jakob Emerson * Louisiana hospital considering service adjustments, denies closure Zachary, La.-based Lane Regional Medical Center is not closing, but facility leaders are evaluating service line adjustments to meet community... By: Madeline Scheetz * 'Automate your bread and butter': How Northwestern processes 400,000 tasks with a 3-person automation team Chicago-based Northwestern Medicine has built a three-person revenue cycle automation team that processed about 400,000 tasks over the past fiscal... By: Alan Condon
Find jobs on Simplify and start your career today
Industries
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$112.4M
Headquarters
Chicago, Illinois
Founded
1927
Find jobs on Simplify and start your career today